On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy. For more information, read the FDA announcement and the Partner Therapeutics press release.
On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy.
For more information, read the FDA announcement and the Partner Therapeutics press release.
